SCI Pharmtech revenue rises to NT$149.0M in 2026 vs NT$51.8M
SCI Pharmtech Inc. reports 2026 revenue of NT$148,954,000 versus NT$51,806,000 in 2025, and Jan–Aug revenue of NT$988,413,000 versus NT$865,442,000 in 2025, per Taiwan Stock Exchange.
SCI Pharmtech Inc. reported revenue of NT$148,954,000 in 2026, compared with NT$51,806,000 in 2025, according to Taiwan Stock Exchange figures in New Taiwan dollars. For Jan-Aug, revenue was NT$988,413,000 versus NT$865,442,000.